title: [Treatment of type 2 diabetes mellitus in patients with chronic kidney disease. Grupo de Trabajo para el Documento de Consenso sobre el tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica].
abstract: Chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) are highly prevalent chronic diseases, which represent an important public health problem and require a multidisciplinary management. T2DM is the main cause of CKD and it also causes a significant comorbidity with regard to non-diabetic nephropathy. Patients with diabetes and kidney disease represent a special risk group as they have higher morbi-mortality as well as higher risk of hypoglycemia than diabetic individuals with a normal kidney function. Treatment of T2DM in patients with CKD is controversial because of the scarcity of available evidence. The current consensus report aims to ease the appropriate selection and dosage of antidiabetic treatments as well as the establishment of safety objectives of glycemic control in patients with CKD.
authors.affiliation: Sociedad Española de Medicina Interna (SEMI), España. Electronic address: ricardogomezhuelgas@hotmail.com.
authors.forename: Ricardo
authors.initials: R
authors.lastname: Gómez-Huelgas
authors.affiliation: Sociedad Española de Nefrología (SEN), Grupo Español de Estudio de la Nefropatía Diabética (GEENDIAB), España.
authors.forename: Alberto
authors.initials: A
authors.lastname: Martínez-Castelao
authors.affiliation: Red de Grupos de Estudio de la Diabetes en Atención Primaria (redGDPS), España.
authors.forename: Sara
authors.initials: S
authors.lastname: Artola
authors.affiliation: Sociedad Española de Nefrología (SEN), Grupo Español de Estudio de la Nefropatía Diabética (GEENDIAB), España.
authors.forename: José Luis
authors.initials: JL
authors.lastname: Górriz
authors.affiliation: Sociedad Española de Diabetes (SED), España.
authors.forename: Edelmiro
authors.initials: E
authors.lastname: Menéndez
mesh_terms: D000419:Albuminuria / Q000209:etiology; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003928:Diabetic Nephropathies / Q000209:etiology; D050171:Dyslipidemias / Q000517:prevention & control; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000453:epidemiology; D007003:Hypoglycemia / Q000139:chemically induced / Q000209:etiology / Q000517:prevention & control; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011379:Prognosis; D051436:Renal Insufficiency, Chronic / Q000150:complications* / Q000378:metabolism; D014652:Vascular Diseases / Q000453:epidemiology
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D010975:Platelet Aggregation Inhibitors
keywords: Ancianos; Cardiovascular risk factors; Chronic kidney disease; Diabetes mellitus tipo 2; Elderly; Enfermedad renal crónica; Factores de riesgo cardiovascular; Type 2 diabetes mellitus